Loading
Alzheimer S Disease / 18F-florbetaben / 18F-PF974 · Phase 1 Trial
ClinicalTrials.gov · July 31, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 registry record describing a planned study to evaluate PDE4B radioligand binding in the medial temporal lobe of participants with AD or MCI versus healthy age- and sex-matched controls using PET imaging with [18F]PF-06445974. No results are available; the study is currently recruiting and remains in early exploratory stages.
Phase 1, Interventional, Single Group, Open label, Diagnostic purpose. Alzheimer s Disease, Mild Cognitive Impairment, Healthy; age from 50 Years; to 100 Years; accepts healthy volunteers. Intervention: One-Arm. Compared with: Age- and sex-matched healthy volunteers who are amyloid-negative. n = 90. 1 site: United States.
This is a Phase 1 registry record describing a planned study to evaluate PDE4B radioligand binding in the medial temporal lobe of participants with AD or MCI versus healthy age- and sex-matched controls using PET imaging with [18F]PF-06445974. No results are available; the study is currently recruiting and remains in early exploratory stages.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a Phase 1 registry record for a planned interventional study with no results posted; it describes study design and enrollment targets only.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07169630). This is a study registration, not published results. Lead sponsor: National Institute of Mental Health (NIMH). Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 90 participants (ESTIMATED). Conditions: Alzheimer s Disease, Mild Cognitive Impairment, Healthy. Interventions: DRUG: 18F-PF974; DRUG: 18F-florbetaben. Primary outcome measures: To determine whether PDE4B radioligand binding is increased in medial temporal lobe of participants with AD or MCI (both A <= positive) compared to age-and sex matched HVs (who are A <= negative. , 48 months. Brief summary: Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflammation is thought to play a role in AD and MCI. Researchers want to know if an enzyme called PDE4B increases inflammation in people with AD or MCI. Objective: To test whether medical imaging using a new radiotracer (\[18F\]PF-06445974) can measure PDE4B in the brains of people with AD or MCI. Eligibility: People aged 50 years and older with AD or MCI. Healthy volunteers are also needed. Design: Participants will have up to 5 clinic visits with 3 imaging scans of the brain. They will have be screened. They will have a physical exam with blood tests. This will include tests of their heart and nerve function, including memory. Participants will have 2 positron emission tomography (PET) scans. One will use a standard radiotracer. The other will use the study radiotracer. They will receive each tracer through a tube attached to a needle inserted into a vein. During the scan with the study tracer, participants will have a second tube inserted into a vein in the wrist; this tube will be used to draw blood during the scan. Participants will lie on a bed that slides into a doughnut-shaped machine. These visits will take about 6 hours each. Participants will have 1 magnetic resonance imaging (MRI) scan. They will lie on a bed that slides into a cylinder. This visit will take up to 2 hours....
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.